# PEER-REVIEW REPORT

**Name of journal:** *World Journal of Psychiatry*

**Manuscript NO:** 90856

**Title:** Evaluating serum CXC 2, sCD22, Lp-PL levels and ratios as biomarkers for diagnosis of Alzheimer's disease

**Provenance and peer review**: Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 06527179

**Position:** Editorial Board

**Academic degree:** BSc, PhD

**Professional title:** Academic Fellow, Academic Research

**Reviewer's Country/Territory:** United Kingdom

**Author's Country/Territory:** China

**Manuscript submission date:** 2023-12-17

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2023-12-24 06:54

**Reviewer performed review:** 2024-01-05 02:55

**Review time:** 11 Days and 20 Hours

| | |
|---|---|
| **Scientific quality** | [ Y] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good<br>[ ] Grade D: Fair [ ] Grade E: Do not publish |
| **Novelty of this manuscript** | [ Y] Grade A: Excellent [ ] Grade B: Good [ ] Grade C: Fair<br>[ ] Grade D: No novelty |
| **Creativity or innovation of this manuscript** | [ Y] Grade A: Excellent [ ] Grade B: Good [ ] Grade C: Fair<br>[ ] Grade D: No creativity or innovation |

| Scientific significance of the conclusion in this manuscript | [ Y] Grade A: Excellent    [   ] Grade B: Good      [   ] Grade C: Fair  [   ] Grade D: No scientific significance |
|---|---|
| Language quality | [ Y] Grade A: Priority publishing   [   ] Grade B: Minor language polishing   [   ] Grade C: A great deal of language polishing   [   ] Grade D: Rejection |
| Conclusion | [ Y] Accept (High priority)    [   ] Accept (General priority)  [   ] Minor revision   [   ] Major revision   [   ] Rejection |
| Re-review | [   ] Yes   [ Y] No |
| Peer-reviewer statements | Peer-Review: [ Y] Anonymous    [   ] Onymous |
| | Conflicts-of-Interest: [   ] Yes   [ Y] No |

## SPECIFIC COMMENTS TO AUTHORS

accept as is. The paper is well written and of interest it concerns quantification of specific genes in serum of AD patients (a.g CXCL12, sCD22, Lp-PLA2 Levels as biomarkers) the data is available there is a table and 2 figures .